NCT04357522View on ClinicalTrials.gov

Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,950

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Pneumonia, Pneumococcal
Interventions
BIOLOGICAL

15-Valent Pneumococcal Conjugate Vaccine

4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.

BIOLOGICAL

13-Valent Pneumococcal Conjugate Vaccine

4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.

Trial Locations (3)

056900

Daming Center for Disease Control and Prevention, Daming

074199

Laishui Center for Disease Control and Prevention, Laishui

050800

Zhengding Center for Disease Control and Prevention, Zhengding

All Listed Sponsors
lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY